Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Synergistic effects of PARP inhibition and cholesterol biosynthesis modulation

ABSTRACT: Investigate the effects of PARP inhibition in different contexts.

ORGANISM(S): Homo sapiens

PROVIDER: GSE230634 | GEO | 2023/06/01

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Synergistic effects of PARP inhibition and cholesterol biosynthesis modulation

Project description:Synergistic effects of PARP inhibition and cholesterol biosynthesis modulation

| PRJNA962032 | ENA

PARP inhibition

Project description:PARP inhibition and the effect on Arabidopsis thaliana high light tolerance

2012-05-01 | E-MTAB-896 | biostudies-arrayexpress

Transcriptional modulation by PRMT5 inhibition with EPZ015666 (GSK3235025)

Project description:Aberrant protein arginine methylation has been observed in multiple cancer types, making it an attractive drug target. Proteins can undergo asymmetric arginine methylation by type I protein arginine methyltransferases (PRMTs), predominately by PRMT1 and to a lesser extent PRMT4, or symmetric arginine methylation by type II PRMTs, predominately PRMT5. Here, we performed targeted proteomics following inhibition of PRMT1, PRMT4, and PRMT5 across cancer cell lines. We found that inhibition of both type I and type II PRMTs suppressed levels of total and phosphorylated ATR protein in cancer cell lines, and down-regulated expression of the ATR gene. Loss of ATR from PRMT inhibition resulted in defective DNA replication stress response activation in following exogenous replication stress. Since PARP inhibitors are known to induce replication stress, we next combined PRMT inhibition with PARP inhibition and found inhibition of PRMT1 or PRMT5 greatly exacerbated PARP inhibitor induced DNA damage. Based on this observation, we assessed the combination of PARP and PRMT inhibition in a panel of cell lines. While inhibition of both type I and type II PRMTs were synergistic with PARP inhibition in both cells with intact and deficient homologous recombination, type I PRMT inhibition resulted in higher toxicity in non-malignant cells. Therefore, we validated the synergy of combined PARP/PRMT5 inhibition in primary patient-derived organoids. Finally, we demonstrate that the combination of PARP and PRMT5 inhibition improves overall survival in both BRCA-mutant and wild-type patient-derived xenograft models without any detectable hematological toxicities typically associated with PARPi combination therapies. Taken together, these results demonstrate that PRMT5 inhibition may be a well-tolerated approach to improve tumor sensitivity to PARP inhibition. .

2023-10-26 | GSE246325 | GEO

Expression profile from murine acute myeloid leukemia cells C1498 with or without PARP-1 inhibition

Project description:Poly(ADP-ribose) polymerase 1 (PARP-1) is abnormally expressed in a wide variety of tumors. Emerging evidence suggests that PARP-1 plays key roles in multiple biologic behaviors of tumors, such as modulation of chromatin structure, regulation of gene transcription, tumor proliferation, apoptosis, and angiogenesis, by acting on different molecular pathways. PARP-1 inhibition can achieve a beneficial outcome in tumor treatment. But the specific mechanism of PARP-1 in acute myeloid leukemia (AML) is still to be discovered. We used microarrays to detail the global gene expression in C1498 with and without PARP-1 inhibition and profile differentially expressed genes that might be involved in PARP-1 regulation in AML.

2016-08-31 | GSE64220 | GEO

Effects of alcohol and PARP inhibition on RNA ribosomal engagement in cortical excitatory neurons

Project description:The objective of the study is to describe the effects of EtOH on excitatory pre-frontal cortical neuronal ribosomal-engagement (RE) transcripts from total-RNA and provides insights into Poly (ADP-ribose) polymerase (PARP)-mediated regulation of EtOH effects (using the PARP inhibitor ABT-888).

2023-04-13 | GSE227947 | GEO

Combined inhibition of TOP1 and PARP: a synergistic therapeutic strategy for PTEN-deficient glioblastoma

Project description:Combined inhibition of TOP1 and PARP: a synergistic therapeutic strategy for PTEN-deficient glioblastoma

| PRJNA934344 | ENA

Effects of PARP inhibition on the transcriptome in BRCA1 wild-type and BRCA1 deficient ovarian cancer cell lines

Project description:Despite numerous therapeutic advances over the years, ovarian cancer, especially high grade serous ovarian carcinoma remains the deadliest gynecological malignancy. Although PARP inhibition has been shown to be an effective (maintenance) therapy for homologous recombination repair deficient or BRCA1 mutated ovarian cancer, there may be further potential for combination therapy with other drugs such as immune checkpoint inhibitors. BRCA1 mutation as well as PARP inhibitor (Olaparib) treatment influenced the activation of immune response pathways such as cGAS-STING signaling and Interferon-alpha response in ovarian cancer cell lines. Bioinformatics functional analyses uncovered further immune related cellular responses and signaling pathways such as JAK-STAT signaling.

2023-08-01 | GSE237361 | GEO

PARP-1/PARP-2 double deficiency results in recurrent early pregnancy loss and decidualization failure in mice

Project description:Specifically, we found inhibition of PARP-1 and PARP-2 catalytic activity, or tissue-specific genetic knockout, results in a severe fertility defect. Transcriptomic analyis uncovered that PARP-1;PARP-2-deficient mice have defects in the progression of stromal cell decidualization manifesting in pregnancy failure

2021-09-13 | GSE169544 | GEO

PRICKLE4 Underlies IDH mutant Tumors Resistance against PARP Inhibition

Project description:PRICKLE4 Underlies IDH mutant Tumors Resistance against PARP Inhibition

| PRJNA1050787 | ENA

A synergistic interaction between HDAC- and PARP inhibitors in childhood tumors with chromothripsis

Project description:Expression data of medulloblastoma patient derived xenograft spheroids upon BGB 290 and romidepsin treatment alone and in combination: Romidepsin and BGB 290 shows synergistic growth inhibition in medulloblastoma patient derived xenograft spheroid models in vitro and in vivo. Chromothripsis is a form of genomic instability characterized by the occurrence of tens to hundreds of clustered DNA double-strand breaks in a one-off catastrophic event. Rearrangements associated with chromothripsis are detectable in numerous tumor entities and linked with poor prognosis in some of these, such as Sonic Hedgehog medulloblastoma, neuroblastoma and osteosarcoma. Hence, there is a need for therapeutic strategies eliminating tumor cells with chromothripsis. Defects in DNA double-strand break repair, and in particular homologous recombination repair, have been linked with chromothripsis. Targeting DNA repair deficiencies by synthetic lethality approaches, we performed a synergy screen using drug libraries (n = 375 compounds, 15 models) combined with either a PARP inhibitor or cisplatin. This revealed a synergistic interaction between the HDAC inhibitor romidepsin and PARP inhibition. Functional assays, transcriptome analyses, and in vivo validation in patient-derived xenograft mouse models confirmed the efficacy of the combinatorial treatment.

2022-02-08 | GSE188894 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data